KR20110052686A - 피리딘 유도체의 결정질 형태 - Google Patents

피리딘 유도체의 결정질 형태 Download PDF

Info

Publication number
KR20110052686A
KR20110052686A KR1020117005159A KR20117005159A KR20110052686A KR 20110052686 A KR20110052686 A KR 20110052686A KR 1020117005159 A KR1020117005159 A KR 1020117005159A KR 20117005159 A KR20117005159 A KR 20117005159A KR 20110052686 A KR20110052686 A KR 20110052686A
Authority
KR
South Korea
Prior art keywords
crystalline form
formula
compound
disorders
methylbenzenesulfonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117005159A
Other languages
English (en)
Korean (ko)
Inventor
클레어 루이스 앤더튼
데이비드 클라팜
로니 맥스웰 로렌스
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20110052686A publication Critical patent/KR20110052686A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020117005159A 2008-08-05 2009-08-04 피리딘 유도체의 결정질 형태 Withdrawn KR20110052686A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
GB0814340.6 2008-08-05

Publications (1)

Publication Number Publication Date
KR20110052686A true KR20110052686A (ko) 2011-05-18

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117005159A Withdrawn KR20110052686A (ko) 2008-08-05 2009-08-04 피리딘 유도체의 결정질 형태

Country Status (14)

Country Link
US (1) US8093242B2 (enExample)
EP (1) EP2321324A1 (enExample)
JP (1) JP2011529942A (enExample)
KR (1) KR20110052686A (enExample)
CN (1) CN102171219A (enExample)
AU (1) AU2009279135B2 (enExample)
BR (1) BRPI0917224A2 (enExample)
CA (1) CA2733235A1 (enExample)
EA (1) EA201170300A1 (enExample)
GB (1) GB0814340D0 (enExample)
IL (1) IL210777A0 (enExample)
MX (1) MX2011001414A (enExample)
WO (1) WO2010015626A1 (enExample)
ZA (1) ZA201100426B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012003435A2 (pt) * 2009-08-27 2016-02-23 Glaxosmithkline Llc formas anidras de um derivado de píridina
CN114306335A (zh) * 2015-05-18 2022-04-12 康堤医疗有限公司 用于治疗性激素依赖性疾病的双重nk-1/nk-3受体拮抗剂
WO2019175253A1 (en) 2018-03-14 2019-09-19 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
MX2022005867A (es) 2019-11-15 2022-06-14 Kandy Therapeutics Ltd Nuevo proceso quimico para la elaboracion de 6-cloro-4-(4-fluoro-2 -metilfenil)piridin-3-amina, un intermediario clave de nt-814.
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912174B1 (en) 1996-07-17 2004-04-28 MERCK & CO., INC. Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
DE602004008631T2 (de) 2003-07-03 2008-07-10 F. Hoffmann-La Roche Ag Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
MY145713A (en) * 2005-09-09 2012-03-30 Smithkline Beecham Corp Hexahydropyrazino [2,1-c][1,4]oxazin-8(1h)-yl pyridine derivatives and their use in the treatment of psychotic disorders

Also Published As

Publication number Publication date
AU2009279135B2 (en) 2012-09-13
BRPI0917224A2 (pt) 2015-11-24
US20110136798A1 (en) 2011-06-09
ZA201100426B (en) 2012-03-28
EA201170300A1 (ru) 2011-08-30
EP2321324A1 (en) 2011-05-18
MX2011001414A (es) 2011-04-04
US8093242B2 (en) 2012-01-10
WO2010015626A1 (en) 2010-02-11
AU2009279135A1 (en) 2010-02-11
CN102171219A (zh) 2011-08-31
GB0814340D0 (en) 2008-09-10
IL210777A0 (en) 2011-03-31
JP2011529942A (ja) 2011-12-15
CA2733235A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
EP4382530A1 (en) Shp2 inhibitor, pharmaceutical composition comprising same, and application thereof
JP3779682B2 (ja) ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンの酒石酸塩及びその医薬組成物
JP5121716B2 (ja) ピリジン誘導体および精神異常の処置におけるそれらの使用
JP6404186B2 (ja) 無水形態のピリジン誘導体
JP2009507801A5 (enExample)
CN102066376B (zh) 马来酸欧维特的无水晶型
KR20110052686A (ko) 피리딘 유도체의 결정질 형태
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
EP4512807A1 (en) Bicycloamine carboxamide derivative
JP5727139B2 (ja) ３−（３−アミノ−２−（ｒ）−ヒドロキシ−プロピル）−１−（４−フルオロ−フェニル）−８−（８−メチル−ナフタレン−１−イルメチル）−１，３，８−トリアザ−スピロ［４．５］デカン−４−オンの塩
EP1674103A1 (en) Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110304

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130426

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid